3.71
+0.41(+12.42%)
Currency In USD
| Previous Close | 3.3 |
| Open | 3.3 |
| Day High | 4.18 |
| Day Low | 3.3 |
| 52-Week High | 4.45 |
| 52-Week Low | 0.64 |
| Volume | 564,772 |
| Average Volume | 2.09M |
| Market Cap | 9.96M |
| PE | -2.56 |
| EPS | -1.45 |
| Moving Average 50 Days | 1.48 |
| Moving Average 200 Days | 1.69 |
| Change | 0.41 |
If you invested $1000 in Lixte Biotechnology Holdings, Inc. (LIXT) 10 years ago, it would be worth $237.82 as of July 16, 2025 at a share price of $3.71. Whereas If you bought $1000 worth of Lixte Biotechnology Holdings, Inc. (LIXT) shares 5 years ago, it would be worth $68.7 as of July 16, 2025 at a share price of $3.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials
GlobeNewswire Inc.
Jul 09, 2025 12:05 PM GMT
Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIX
Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering
GlobeNewswire Inc.
Jul 08, 2025 8:05 PM GMT
PASADENA, CALIF, July 08, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a registered direct offering with accredited investors for
Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market
GlobeNewswire Inc.
Jul 02, 2025 8:05 PM GMT
PASADENA, CALIF, July 02, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a private placement with accredited investors for the purc